SIGHT SCIENCES INC

Company Overview

Sight Sciences (SGHT) develops interventional ophthalmology devices focused on microinvasive glaucoma surgery (MIGS) and evaporative dry eye disease (DED), with principal products OMNI, SION and TearCare. Surgical Glaucoma drives nearly all revenue (~95% in FY2024) — FY2024 revenue was $79.9M with an estimated ~295k surgical uses and ~65k TearCare uses through year-end 2024; Surgical Glaucoma adoption and TearCare reimbursement are core growth levers. The company outsources manufacturing (notably China), sells directly in the U.S./Europe with distributor partners elsewhere, and faces key operational risks from reimbursement (MAC LCDs), tariffs, competition and supplier concentration. Management is investing in clinical evidence and new product launches (OMNI Edge targeted H1 2025) while operating with ongoing net losses and limited-term liquidity (cash ~$120M at 12/31/24; $101.5M at 6/30/25; $40M drawn on a term loan).

Executive Compensation Practices

Given the early-revenue, evidence-driven medical device model and ongoing losses, executive pay is likely skewed toward equity and milestone-based incentives rather than large cash bonuses; filings specifically call out stock-based compensation as a material accounting judgment. Short-term incentives will plausibly be tied to commercial metrics (procedure volume, revenue growth in Surgical Glaucoma and TearCare), reimbursement milestones (payer coverage/LCD outcomes) and gross-margin improvement (tariff mitigation, supply reshoring). Long-term incentives are likely structured around product adoption, clinical-trial and regulatory milestones (e.g., OMNI Edge launch, payer coverage wins) and retention awards to maintain key commercial talent amid cash discipline. The company’s recent reductions in SG&A (including lower stock‑based comp and bonuses) and the existence of a term loan with covenants suggest compensation committees may prioritize cash conservation, covenant compliance and equity dilution management when setting future packages.

Insider Trading Considerations

Insider activity at Sight Sciences is likely to cluster around high‑impact, company‑specific events: clinical trial readouts/publications, MAC/LCD or payer coverage announcements, product-launch news, tariff or supply‑chain updates, and financing or covenant developments. Because equity is a material component of pay, expect insider transactions driven by option exercises, RSU vesting and tax-liquidity needs following positive share moves; conversely, insiders may hold during negative press to signal confidence. Watch for trading blackout windows around earnings, regulatory submissions and reimbursement rulings, and for 10b5‑1 plans which are common in small-cap device firms to manage the timing of predictable sales. Finally, concentrated insider ownership and upcoming financing needs increase the probability of observable selling around financings or to meet tax/household liquidity needs, so monitor timing relative to clinical and reimbursement catalysts.